To verify that Foxa2 attenuates steatosis through the NF-κB/IKK pathway, OA-induced HepG2 cells were treated with oe-Foxa2 and LPS (NF-κB/IKK pathway activator). The gene discussed is FOXA2; the disease is steatosis.